An Ipamorelin test report can answer different questions
A study of a compound and a test of a particular vial aren't interchangeable. These sources concern the compound.
If you're looking for an Ipamorelin test report, first check what was tested. A clinical trial asks about effects in people. A laboratory report may describe one sample. Neither can quietly take the other's place. The question behind the test matters as much as its name.
The links below lead to the studies and FDA records discussed here. They don't certify a product. We haven't tested a vial or issued a certificate. For each source, the people or animals involved, the treatment route and the question being asked set the limits of the answer.
Where the selectivity description began
Raun and colleagues, 1998. Experiments included rat cells in a lab, rats and pigs. The selective hormone response is animal evidence, not a human safety finding. It doesn't show that only helpful effects occur.
The human hormone-pulse study
Gobburu and colleagues, 1999. This infusion study involved healthy men, with treatment delivered into a vein. Researchers followed blood levels and a short hormone pulse. They didn't test better sleep, strength or body composition, or establish a home-injection schedule.
Eating after surgery — the published trial
Beck and colleagues, 2014. Patients received Ipamorelin or placebo during bowel-surgery recovery. The main comparison asked when they could tolerate a meal. The difference wasn't statistically significant; the trial didn't establish a benefit.
The mouse body-fat experiment
Lall and colleagues, 2001. Ipamorelin increased body fat in mice, partly without depending on growth hormone. That challenges a simple fat-loss explanation. It doesn't establish whether a person would gain or lose fat.
The larger completed trial record
ClinicalTrials.gov, NCT01280344. This trial enrolled 320 people after bowel surgery and finished in 2014. At the October 1, 2026 source check, the registry had no posted results and no outcome paper was found. Completion alone doesn't tell us whether treatment helped.
FDA’s ingredient safety page
FDA gives April 22, 2026 as this page's content date. The acetate listing under 503B Category 2 concerns significant safety risks at FDA-registered outsourcing facilities. These facilities compound sterile medicines. Its 503A nomination for patient-specific compounding is recorded separately as withdrawn. Taking back a nomination isn't clearance.
FDA’s detailed Ipamorelin review
FDA's material for the October 2024 compounding advisory meeting covers ingredient forms, human studies and safety gaps. It separates hospital findings from concerns based on growth-hormone medicines. It also flags impurities and peptide clumping as possible triggers for immune reactions.
FDA's explanation of compounded medicines
Compounded medicines reach patients without FDA approval. Patient-specific 503A compounding and registered 503B outsourcing facilities follow separate conditions. A prescription leaves the ingredient rules in place.